Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En 48-måneders undersøgelse for at evaluere langsigtet effektivitet af Elocta på ledsundhed (A-MORE)

18. september 2026 opdateret af: Swedish Orphan Biovitrum

En 48-måneders, multi-center, observationsundersøgelse for at evaluere langsigtet effektivitet af Elocta på ledsundhed

This is a 48-month observational, prospective, multicentre study. The overall aim of the study is to evaluate the long-term effectiveness of Elocta treatment on joint health in patients treated prophylactically with Elocta in a real-world setting.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Haemophilia A is a rare genetic disorder estimated to occur in one out of 10,000 live births, characterized by a deficiency in coagulation factor VIII causing impaired haemostasis and prolonged bleeding episodes. Moderate haemophilia, defined as < 5%, and severe haemophilia, defined as < 1% of normal factor VIII activity result in frequent and spontaneous bleeds into muscles and joints, commonly the elbows, knees, and ankles. Bleeding into joints can cause acute pain and swelling and can result in reduced joint range of motion, long-term cartilage damage and debilitating haemophilic arthropathy. Early use of prophylaxis with factor VIII replacement is recommended following diagnosis of haemophilia A to maintain joint health and prevent joint destruction. However, despite the use of prophylaxis many patients still experience joint bleeds which may lead to joint deterioration over time. The risk of joint bleeds increases with the amount of time spent below certain FVIII trough levels, e.g. 1, 3 or 5 IU/dL. Thus, there is probably a relation between the intensity of the prophylactic treatment regimen and joint health. Elocta is an extended half-life rFVIII product (EHL rFVIII), with a slower clearance as compared to conventional FVIII products. Treatment with Elocta will therefore provide the treater with a greater flexibility for individualizing prophylaxis as compared to conventional FVIII. Higher trough levels can be reached with Elocta without increasing factor usage or injection frequency. The treater can instead choose to reduce the injection frequency or the factor consumption without lowering trough levels.

Patients may limit their physical activities due to fear of bleeding if they are unaware of their current FVIII level. Patient apps and wearables are now available which allow patients to view their predicted FVIII levels, and capture health-related data (such as bleedings, pain, well-being, physical activity levels etc.). This data can be shared with the treating physician supporting the planning to individualize the patient's factor treatment based on current lifestyle, health status and physical activity levels. Florio, a certified medical device used as part of routine clinical practice, is such an app, and the data output and patient feedback on their activity levels and sense of protection while using Florio will be analysed as exploratory objectives in this study.

The main purpose of this study is to evaluate the effectiveness of Elocta on joint health over a long observation period (48 months). The study will also explore the influence on long term joint health of different Elocta prophylaxis regimens leading to different trough levels and if the extent of patients' physical activity levels can be associated with predicted FVIII levels.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

427

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Canterbury, Det Forenede Kongerige
        • East Kent Hospitals University NHS Foundation Trust, Kent Haemophilia and Thrombosis Centre, Kent and Canterbury Hospital
      • London, Det Forenede Kongerige
        • Great Ormond Street Hospital, Royal London Hospital for Integrated Medicine
      • Tallinn, Estland
        • Lastehaigla, Tallinn (Tallinn Children´s Hospital)
      • Tallinn, Estland
        • The North Estonia Medical Centre Hematoloogiakeskus, Regionalhaigla
      • Helsinki, Finland
        • Helsinki University Central Hospital, New Children Hospital
      • Turku, Finland
        • Turku University Central Hospital, Paediatric and adolescent haematology and oncology clinic
      • Thessaloniki, Grækenland
        • Ippokrateio Hospital Thessaloniki (adult department)
      • Thessaloniki, Grækenland
        • Ippokrateio Hospital Thessaloniki (pediatric department)
      • Groningen, Holland
        • University Medical Center Groningen/UMCG
      • Bari, Italien
        • University of Bari Aldo Moro (Centro Emofilia Policlinico - Pediatria U.O.)
      • Cesena, Italien
        • AUSL Romagna Centro Emofilia U.O.C., Medicina Trasfusionale Dipartimento Patologia, Clinica Ospedale M. Bufalini
      • Genova, Italien
        • Giannina Gaslini Institute
      • Milan, Italien
        • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
      • Parma, Italien
        • University Hospital of Parma, AOUP, Haemophilia Center
      • Rome, Italien
        • Uo Malattie Emorragiche e Trombotiche Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Universitá Catolica del Sacro Coure
      • Torino, Italien
        • Azienda Ospedaliera Città della Salute e della Scienza di Torino Regina Margherita
      • Muscat, Oman
        • The Royal Hospital
      • Riyadh, Saudi Arabien
        • Dr Suliman Al Habib Hospital Riyadh
      • Riyadh, Saudi Arabien
        • King Faisal Specialised Hospital, KFSH Riyadh, Children
      • Riyadh, Saudi Arabien
        • King Faisal Specialist Hospital KFSH, Adults
      • Riyadh, Saudi Arabien
        • Riyadh Military Hospital (P.S.M.C)
      • Bern, Schweiz
        • Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor Inselspital
      • Lausanne, Schweiz
        • Service et Laboratoire central d'hématologie, Adults
      • Sankt Gallen, Schweiz
        • Zentrum für Labormedizin
      • Zurich, Schweiz
        • Universitätsspital Zürich Klinik für Medizinische Onkologie und Hämatologie
      • Ljubljana, Slovenien
        • University Medical Centre Ljubljana Division of Paediatrics
      • Barcelona, Spanien
        • Sant Johan De Deu
      • Barcelona, Spanien
        • Hospital de la Santa Creu i Sant Pau
      • Barcelona, Spanien
        • Hospital Vall d'Hebron
      • Cruces, Spanien
        • Hospital Universitario Cruces
      • Donostia / San Sebastian, Spanien
        • Hospital Universitario Donostia
      • Murcia, Spanien
        • Hospital Virgen de la Arrixaca
      • Málaga, Spanien
        • Hospital Universitario Carlos Haya
      • Navarro, Spanien
        • Complejo Hospitalario de Navarra
      • Oviedo, Spanien
        • Hospital Universitario Central de Asturias (HUCA)
      • Palma de Mallorca, Spanien
        • Hospital Universitario Son Espases
      • Seville, Spanien
        • Hospital Universitario Virgen del Rocío
      • Vigo, Spanien
        • Hospital Alvaro Cunqueiro
      • Gothenburg, Sverige
        • Hematologimottagning Sahlgrenska
      • Malmö, Sverige
        • Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital Malmö
      • Brno, Tjekkiet
        • University Hospital Brno
      • Ostrava, Tjekkiet
        • University Hospital Ostrava
      • Prague, Tjekkiet
        • Dept. of Pediatric Haematology and Oncology, University Hospital Motol
      • Berlin, Tyskland
        • Charité-Universitätsmedizin Berlin Campus Virchow Klinikum
      • Bonn, Tyskland
        • Universitätsklinikum Bonn AöR, Institut für Experimentelle Hämatologie und Transfusionsmedizin
      • Frankfurt, Tyskland
        • Hämostaseologie/Hämophiliezentrum, Medizinische Klinik 2 Institut für Transfusionsmedizin, Universitätsklinikum
      • Frankfurt, Tyskland
        • Universitätsklinikum Frankfurt - Klinik für Kinder- und Jugendmedizin
      • Hamburg, Tyskland
        • Universitätsklinikum Hamburg-Eppendorf (UKE)
      • Hanover, Tyskland
        • Medizinische Hochschule Hannover
      • Hanover, Tyskland
        • Werlhof-Institut für Hämostaseologie GmbH
      • Heidelberg, Tyskland
        • SRH-Klinikum Heidelberg
      • Mörfelden-Walldorf, Tyskland
        • HZRM Hämöphilie Zentrum Rhein Main
      • München, Tyskland
        • Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital am Universitätsklinikum München

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn
  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Patients diagnosed with haemophilia A regardless of severity, of any gender and age, on factor treatment with Elocta according to usual clinical practice.

Beskrivelse

Inclusion Criteria:

  • Provided signed and dated informed consent by the patient, or the patient's legally authorized representative(s) for patients under the legal age, before any study-related activities are undertaken. Assent should be obtained from paediatric patients according to local regulations
  • Have a diagnosis of haemophilia A
  • At enrolment on prophylactic treatment with Elocta, independent of participation in the study

Exclusion Criteria:

  • Enrolment in another concurrent clinical interventional study, or intake of an Investigational Medicinal Product (IMP), within three months prior to inclusion in this study
  • Presence of factor VIII antibodies (inhibitors) (≥0.60 Bethesda Unit [BU]/mL) at the latest available inhibitor test

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Hemophilia A patients

All patients diagnosed with haemophilia A regardless of severity, on factor treatment with Elocta according to usual clinical practice.

Extended half-life factor VIII product

Andre navne:
  • efmoroctocog alfa
  • UDVÆLG
  • rFVIIIFc

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Joint health: Target joint development
Tidsramme: 48 months

Number of target joints

48 months
Joint health: Target joint resolution
Tidsramme: 48 months

Number of resolved target joints

48 months
Joint health: Target joint recurrence
Tidsramme: 48 months

Number of recurring target joints

48 months
Joint health: Annualised joint bleeding rate (AJBR) for treated bleeds
Tidsramme: 48 months

Number of joint bleeding events per year, for treated bleeds

48 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Disease Activity (hypertrophic synovium) and Disease Damage (Cartilage or Bone) scores for elbows, knees and ankles
Tidsramme: 48 months

The Haemophilia Early Arthropathy Detection with UltraSound (HEAD-US) protocol will be used. The total score represents the sum of item scores for abnormalities detected. Its values range from 0 (minimum) to 8 (maximum). A higher score indicates a worse outcome.

48 months
Global Gait Score, and/or joint score items for elbows, knees and ankles.
Tidsramme: 48 months

The Haemophilia Joint Health Score (HJHS) system will be used. Global Gait Score, and/or Joint score items (swelling, duration of swelling, muscle atrophy, axial alignment, crepitus on motion, flexion loss, instability, extension loss, joint pain, strength, gait) for elbows, knees and ankles.

The minimum score per joint is 0, the maximum score is 20. The overall total joint score (range 0-120) is the sum of the 6 six index joint (elbows, knees and ankles) scores. A higher score indicates a worse outcome.

48 months
Joint and physical evaluation for elbows, knees and ankles.
Tidsramme: 48 months

The WFH Physical Examination Score (AKA Gilbert Score) will be used. Joint evaluation (pain, bleeding, physical examination and radiologic evaluation) and physical evaluation (swelling, muscle atrophy, axial deformity, crepitus on motion, range of motion, flexion contracture, and instability). A higher score indicates a worse outcome.

48 months

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Effectiveness of Elocta: Annualised bleeding rate (ABR) for treated bleeds
Tidsramme: 48 months

Number of bleeding events per year, for treated bleeds

48 months
Effectiveness of Elocta: Annualised bleeding rate (ABR) for all bleeds
Tidsramme: 48 months

Number of bleeding events per year, for all bleeds

48 months
Effectiveness of Elocta: Occurrence of zero (0) joint bleeds
Tidsramme: 48 months

Percentage (%) of study population with zero (0) joint bleeds

48 months
Effectiveness of Elocta: Work productivity and impairment
Tidsramme: 48 months

Assessed by WPAI-SHP questionnaire

48 months
Effectiveness of Elocta: Quality of Life
Tidsramme: 48 months

Assessed by Haemo-QoL/Haem-A-QoL questionnaire

48 months
Effectiveness of Elocta: Physical activity level
Tidsramme: 48 months

Assessed by the Saltin-Grimby scale

48 months
Effectiveness of Elocta: Quality of Life
Tidsramme: 48 months

Assessed by EQ-5D-5L/EQ-5D-Y questionnaire

48 months
Effectiveness of Elocta: Severity of joint health
Tidsramme: 48 months

Assessed by Patient Global Impression of Severity of Joint Health questionnaire

48 months
Effectiveness of Elocta: FVIII plasma levels
Tidsramme: 48 months

Percentage (%) of FVIII plasma level

48 months
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
Tidsramme: 48 months

Assessed by medication dose

48 months
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
Tidsramme: 48 months

Assessed by total number of exposure days per medication

48 months
Usage of Elocta: Annualised injection frequency per subject
Tidsramme: 48 months

Assessed by prescription

48 months
Usage of Elocta: Annualised factor consumption per subject
Tidsramme: 48 months

Assessed by prescription [IU/kg]

48 months
Usage of Elocta: Adherence
Tidsramme: 48 months

Investigator assessed (Percentage (%))

48 months
Exploratory Objective
Tidsramme: 48 months

Influence of different Elocta prophylaxis regimens on long term joint health

48 months
Exploratory Objective: Impact of florio HAEMO on patients' sense of protection and their activity level
Tidsramme: 48 months

Results from questionnaire on impact of florio HAEMO tools on patients' sense of protection and their activity level

48 months
Exploratory Objective: Explore adherence to prescribed treatment regimen
Tidsramme: 48 months

florio HAEMO captured treatment adherence scores

48 months
Exploratory Objective: Explore relationship between predicted FVIII levels and physical activity
Tidsramme: 48 months

florio HAEMO captured predicted FVIII levels, florio HAEMO captured physical activity (type, duration, heart rate and steps)

48 months
Exploratory Objective: Explore timing of bleeds in relation to predicted FVIII levels and physical activity
Tidsramme: 48 months

florio HAEMO captured bleed data (timing, location, cause, treated/untreated), florio HAEMO captured injection data (time, dose), florio HAEMO captured predicted FVIII levels

48 months
Exploratory Objective: Explore the use of Florio to characterise pain and well-being
Tidsramme: 48 months

florio HAEMO captured pain data (time, location, cause, intensity), florio HAEMO captured well-being data

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Tidsramme: 48 months

Target joint development, resolution and recurrence

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Tidsramme: 48 months

Annualised joint bleeding rate (AJBR) for treated bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Tidsramme: 48 months

Ultrasound (HEAD-US)

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Tidsramme: 48 months

Clinical joint scoring (HJHS)

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Tidsramme: 48 months

Annualised bleeding rate (ABR) (based on bleeding episodes assessed according to local practice) for all bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Tidsramme: 48 months

Occurrence of zero (0) joint bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Tidsramme: 48 months

Quality of Life assessed by Haemo-QoL/Haem-A-QoL

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Tidsramme: 48 months

Physical activity level assessed by the Saltin-Grimby scale

48 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Study Physician, Swedish Orphan Biovitrum

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

30. marts 2020

Primær færdiggørelse (Faktiske)

4. maj 2026

Studieafslutning (Faktiske)

4. maj 2026

Datoer for studieregistrering

Først indsendt

20. februar 2020

Først indsendt, der opfyldte QC-kriterier

2. marts 2020

Først opslået (Faktiske)

3. marts 2020

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

22. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner